Role of FLT PET in malignant pleural mesothelioma - prediction of response to chemotherapy

FLT PET 在恶性胸膜间皮瘤中的作用 - 预测化疗反应

• 批准号: nhmrc : 446805
• 负责人: A/Pr Roslyn Francis
• 金额: $ 6.24万
• 依托单位: The University of Western Australia
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Strategic Awards
• 财政年份: 2007
• 资助国家: 澳大利亚
• 起止时间: 2007-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/role-flt-pet-response-chemotherapy/96835
• 关键词: Role; FLT; PET; malignant; pleural

Mesothelioma is a cancer of the lining of the lung. Chemotherapy is often used to treat patients in order to reduce their symptoms and to improve quality and length of life. Not all patients however benefit from chemotherapy, and most patients will experience some side-effects. Currently CT scans are used to assess response to chemotherapy, however the way that mesothelioma grows makes measuring response difficult. CT scans also are not very sensitive in detecting response early - often 3 or 4 cycles of treatment (3-4 months) are required before benefit is seen. A test that could predict which patients were benefiting after only 1 cycle (3-4 weeks) of chemotherapy would be a great advantage, and may spare some patients unnecessary and potentially toxic treatment. Fluorothymidine (FLT) is a radioactive tracer that, after injection into a vein, is taken up by dividing cells. Tumour cells usually divide more actively than surrounding normal cells, and therefore when a positron emission tomography (PET) scan is performed it will demonstrate the tumour as a 'hot spot'. The amount of FLT uptake into the tumour depends on how much DNA synthesis (active cell division) is occurring. After chemotherapy, if the tumour responds it would be expected that the amount of FLT in the tumour will reduce. This can be assessed by repeating the FLT PET scan after the first cycle of chemotherapy. This study aims to assess the ability of the change in FLT uptake in mesothelioma after 1 cycle of chemotherapy to predict response, as measured on CT scans, and patient outcomes such as quality of life and survival. It is hoped that if successful this type of scan may improve patient care by selecting those who are likely to benefit from chemotherapy early and avoid unnecessary toxicity to patients who will not benefit from the treatment.

间皮瘤是一种肺癌的衬里。化疗通常用于治疗患者，以减轻其症状并提高生活质量和寿命。然而，并非所有患者都能从化疗中获益，大多数患者会出现一些副作用。目前，CT扫描用于评估对化疗的反应，但间皮瘤的生长方式使测量反应变得困难。CT扫描在早期检测反应方面也不是很敏感-通常需要3或4个治疗周期（3-4个月）才能看到益处。一项可以预测哪些患者在1个周期（3-4周）的化疗后受益的测试将是一个很大的优势，并可能使一些患者免于不必要的和潜在的毒性治疗。氟胸苷（FLT）是一种放射性示踪剂，注射到静脉后，被分裂细胞吸收。肿瘤细胞通常比周围的正常细胞分裂更活跃，因此当进行正电子发射断层扫描（PET）时，它将显示肿瘤为“热点”。FLT摄取到肿瘤中的量取决于DNA合成（活跃的细胞分裂）的发生量。化疗后，如果肿瘤有反应，预计肿瘤中FLT的量将减少。这可以通过在第一个化疗周期后重复FLT PET扫描来评估。本研究旨在评估间皮瘤患者在1个化疗周期后FLT摄取的变化预测疗效（通过CT扫描测量）和患者结局（如生活质量和生存期）的能力。希望这种类型的扫描如果成功，可以通过选择那些可能从早期化疗中受益的患者来改善患者护理，并避免对那些不会从治疗中受益的患者产生不必要的毒性。